Petros Pharmaceuticals (PTPI) Stock Price, News & Analysis

Company Overview

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.

Key Stats

• Today's Range: $0.26 to $0.29
• 50-Day Range: $0.27 to $0.42
• 52-Week Range: $0.26 to $2.27
• Volume: 285,036 shs
• Average Volume: 526,923 shs
• Market Capitalization: $2.71 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.00
• Consensus Rating: Buy

Petros Pharmaceuticals Stock Analysis - MarketRank™

Petros Pharmaceuticals scored higher than 66% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Petros Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Petros Pharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Petros Pharmaceuticals is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Petros Pharmaceuticals is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Petros Pharmaceuticals has a P/B Ratio of 0.07. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.19% of the float of Petros Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Petros Pharmaceuticals has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Petros Pharmaceuticals has recently decreased by 27.19%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Petros Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Petros Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.19% of the float of Petros Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Petros Pharmaceuticals has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Petros Pharmaceuticals has recently decreased by 27.19%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 1.43

News Sentiment

Petros Pharmaceuticals has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Petros Pharmaceuticals this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Petros Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

12.25% of the stock of Petros Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 12.34% of the stock of Petros Pharmaceuticals is held by institutions.

PTPI Stock Analysis - Frequently Asked Questions

How have PTPI shares performed this year?

Petros Pharmaceuticals' stock was trading at $1.41 at the beginning of the year. Since then, PTPI stock has decreased by 80.8% and is now trading at $0.2703.
View the best growth stocks for 2024 here.

When did Petros Pharmaceuticals' stock split?

Petros Pharmaceuticals shares reverse split before market open on Wednesday, November 30th 2022. The 1-10 reverse split was announced on Wednesday, November 30th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 30th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Petros Pharmaceuticals?

Shares of PTPI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Petros Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Petros Pharmaceuticals investors own include Predictive Oncology (POAI), Ford Motor (F), Wells Fargo & Company (WFC), Bank of America (BAC), Abbott Laboratories (ABT), Cricut (CRCT) and JPMorgan Chase & Co. (JPM).

Company Calendar

• Today: 11/15/2024
• Next Earnings (Estimated): 11/20/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PTPI
• CUSIP: N/A
• CIK: 1815903
• Web: www.petrospharma.com
• Phone: 973-242-0005
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $4.00
• High Stock Price Target: $4.00
• Low Stock Price Target: $4.00
• Potential Upside/Downside: +1,379.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($6.54)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-8,160,000.00
• Net Margins: N/A
• Pretax Margin: -171.18%
• Return on Equity: -95.40%
• Return on Assets: -27.43%

Debt

• Debt-to-Equity Ratio: 0.71
• Current Ratio: 1.40
• Quick Ratio: 1.26

Sales & Book Value

• Annual Sales: $5.82 million
• Price / Sales: 0.46
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.04 per share
• Price / Book: 0.07

Miscellaneous

• Outstanding Shares: 10,010,000
• Free Float: 8,783,000
• Market Cap: $2.71 million
• Optionable: Not Optionable
• Beta: 2.11